EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE 
EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE
ASH 2019, Orlando – More than 25.000 attendees from more than 115 countries gather together in the 61st American Society of Hematology (ASH) Annual Congress. This is the largest world congress of hematology and will be held from today to 10 December 2019 in Orlando, Florida, USA.
ASH 2019, Orlando – New data presented by the HARMONY Alliance validate the current prognostic tool for Multiple Myeloma and have identified new parameters to improve the staging of the disease according to a press release publish by the Harmony Alliance. Myeloma Patients Europe (MPE) is part of the HARMONY Patient Cluster which is a unique group of 7 European Patient Umbrella Organizations working in the different areas of hematological diseases within the HARMONY…
MPE is looking for a Senior Office Assistant. Would you like to join the MPE team? Apply for this job offer by sending your CV and motivation letter to Ananda Plate . Full time / permanent Approx. 10 days of travel per year Munich, Germany Salary: 35.000-40.000 EUR GROSS per year
More than 900 myeloma abstracts (posters and oral sessions) will be presented in the largest world congress of hematology: the American Society of Hematology (ASH) Annual Meeting 2019 that will be held from 7 to 10 December 2019 in Orlando, Florida, USA.
It is with great sadness that we share that our friend, colleague and Board member Lisa Kotschi passed away in the night of the 21st November 2019.
Myeloma Patients Europe (MPE) is holding another round of Myeloma Community Advisory Board (Myeloma-CAB) meetings from 17 – 18 November in Munich, Germany. The Myeloma-CAB focuses on providing patient perspectives and advice on clinical development in myeloma, challenges in access to myeloma medicines and patient engagement in myeloma research and development. These meeting ensure meaningful and systematic engagement with the patient community in Europe.
The randomized, placebo-controlled, double-blind Phase 3 clinical trial TOURMALINE-MM4 showed significant improvement in Progression-Free Survival (PFS) of Ixazomib (commercialised by Takeda as Ninlaro) as first line maintenance therapy versus placebo in adult myeloma patients not treated with stem cell transplantation. This clinical trial is the first industry sponsored phase 3 trial to explore the concept of “switch” maintenance, the use of medicines not included in initial induction therapy, in this setting.
The professional society for health economics and outcomes research, ISPOR, organises its annual meeting in Copenhagen, Denmark. From 2 to 6 November experts attending this meeting will debate value in healthcare beyond cost-containment and short-term interventions.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the drug daratumumab (Darzalex®, commercialised by Janssen).
